Vamorolone by ReveraGen BioPharma for Becker Muscular Dystrophy: Likelihood of Approval
Vamorolone is under clinical development by ReveraGen BioPharma and currently in Phase II for Becker Muscular Dystrophy. According to GlobalData, Phase II drugs for Becker Muscular Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vamorolone LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Vamorolone overviewVamorolone (Agamree) acts as a corticosteroid. It is formulated as suspension for oral route of administration. Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. Vamorolone (VBP-15) is under development for the treatment of mild or moderately active ulcerative colitis, Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, asthma, chronic obstructive pulmonary disorder, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, ANCA-associated vasculitis, juvenile dermatomyositis, calpain 3 deficiency (LGMD2A), limb girdle muscular dystrophy type 2B (LGMD2B) and was under development for the treatment of sickle cell anemia, cystic fibrosis and systemic juvenile idiopathic arthritis (SJIA). It is administered orally as suspension. Vamorolone is a dissociative delta-9, 11 glucocorticoid analogue, a steroidal drug. It targets NR3C1.ReveraGen BioPharma overviewReveraGen BioPharma (ReveraGen) operates as a clinical-stage drug development company that develops therapeutics for Duchenne muscular dystrophy. The company’s lead compound, VBP15 is a novel anti-inflammatory drug candidate used in the treatment of Duchenne muscular dystrophy. Its pipeline products are also used for the treatment of various indications such as cystic fibrosis, inflammatory bowel disease, sickle cell anemia and others. The company’s compounds improve heart function, and membrane stabilization properties to counteract dystrophin deficiency. It offers management of clinical trial data in adult volunteers. ReveraGen is headquartered in Rockville, Maryland, the US. For a complete picture of Vamorolone's drug-specific PTSR and LoA scores, buy the report here.
What's Your Reaction?
